The US Food and Drug Administration is asking cancer drug sponsors to think about the studies intended to support accelerated approval, as well as those aimed at confirming clinical benefit postapproval, as a single package when bringing their development plans to the agency.
The goal is to have an early, comprehensive discussion with the agency to ensure that appropriate data are generated for...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?